Sanofi has acquired the American Translate Bio. This was reported by the French pharmaceutical company on Tuesday morning.

Sanofi pays $ 38.00 per share Translate Bio in cash. With this, the American company, a specialist in mRNA, is valued at 3.2 billion dollars. That means a 56% Premium. The acquisition is expected to be completed in the third quarter. The board of both companies supports the acquisition.

Sanofi has been working with Translate Bio since June 2018.

Load More Related Articles
Load More In Business

Leave a Reply

Your email address will not be published.

Check Also

Trump officially confirms his presidential ambitions

Donald Trump wants to become president of the United States again. He officially stood for…